Patents by Inventor Derrick S. Katayama

Derrick S. Katayama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE INTRANASAL FORMULATIONS OF CARBETOCIN
    Publication number: 20230201300
    Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Prader-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.
    Type: Application
    Filed: February 21, 2023
    Publication date: June 29, 2023
    Applicant: LEVO THERAPEUTICS, INC.
    Inventors: Mark C. Manning, Ryan E. Holcomb, Derrick S. Katayama, Christopher Bryant
  • METHODS AND COMPOSITIONS COMPRISING SURFACTANT PROTEIN D (SP-D)
    Publication number: 20210121536
    Abstract: Some embodiments provided herein relate to methods and pharmaceutical compositions comprising recombinant human surfactant protein D or active fragments thereof. Some such embodiments include solutions or suspensions, and lyophilized solid forms of recombinant human surfactant protein D or active fragments thereof.
    Type: Application
    Filed: March 27, 2019
    Publication date: April 29, 2021
    Inventors: Jan Susan Rosenbaum, Mark Cornell Manning, Derrick S. Katayama, Giovanni M. Pauletti, Shawn Grant, Ryan Holcomb
  • Methods of treating prader-willi syndrome with carbetocin
    Patent number: 10967040
    Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: April 6, 2021
    Assignee: Levo Therapeutics, Inc.
    Inventors: Mark C. Manning, Ryan E. Holcomb, Derrick S. Katayama, Christopher Bryant, Sara Cotter, Joseph William Cormier
  • STABLE INTRANASAL FORMULATIONS OF CARBETOCIN
    Publication number: 20200353029
    Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.
    Type: Application
    Filed: July 24, 2020
    Publication date: November 12, 2020
    Applicant: Levo Therapeutics, Inc.
    Inventors: Mark C. Manning, Ryan E. Holcomb, Derrick S. Katayama, Christopher Bryant, Sara Cotter, Joseph William Cormier
  • STABLE INTRANASAL FORMULATIONS OF CARBETOCIN
    Publication number: 20200093884
    Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.
    Type: Application
    Filed: September 20, 2019
    Publication date: March 26, 2020
    Inventors: Mark C. MANNING, Ryan E. Holcomb, Derrick S. Katayama, Christopher Bryant